Press release
Merkel Cell Carcinoma Pipeline Outlook Report 2025: Key 14+ Companies and Breakthrough Therapies Shaping the Future Landscape
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Merkel Cell Carcinoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Merkel Cell Carcinoma Pipeline Insights Report
* In August 2025, Incyte Corporation announced a study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
* In August 2025, Replimune Inc . conducted a Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic cell transplant and experiencing subsequent documented locally advanced or metastatic cutaneous malignancies. The study will enroll a total of 65 evaluable patients.
* DelveInsight's Merkel Cell Carcinoma pipeline report depicts a robust space with 14+ active players working to develop 14+ pipeline therapies for Merkel Cell Carcinoma treatment.
* The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.
* Promising Merkel Cell Carcinoma Therapies such as Avelumab, Pembrolizumab, MLN0128, KRT-232, Retifanlimab, Ipilimumab and others.
Learn how leading Merkel Cell Carcinoma Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Merkel Cell Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Merkel Cell Carcinoma Emerging Drugs Profile
* Domatinostat: 4SC
Domatinostat is an orally administered histone deacetylase (HDAC) inhibitor with a unique mode of action that was designed to strengthen the body's own anti-tumor immune response. Domatinostat "opens" the tumor microenvironment and encourages infiltration of immune cells into the tumor. To advance the development program, 4SC has also signed a drug supply agreement with Merck KGaA for avelumab (anti-PD-L1 antibody) to conduct a Phase II clinical trial of domatinostat in combination with avelumab in advanced-stage Merkel cell carcinoma (MCC) patients progressing on previous anti-PD-(L)1 monotherapy (MERKLIN 2).
* Cavrotolimod: Exicure
Cavrotolimod (AST-008) is a toll-like receptor 9 agonist designed to activate the innate immune system and induce a potent anti-cancer immune response, especially in combination with checkpoint inhibitors. During the first half of 2019, five clinical trial sites were opened and began dosing patients for the Phase I/II clinical trial. The Phase 1b stage was an open-label, multi-center trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral cavrotolimod (AST-008) injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors. The U.S. Food and Drug Administration (FDA) has granted two Fast Track designations to cavrotolimod (AST-008). Exicure initiated the Phase II stage of the clinical trial with dose-expansion cohorts of intratumoral cavrotolimod in combination with approved checkpoint inhibitors to treat two cohorts of patients with locally advanced or metastatic MCC or CSCC.
The Merkel Cell Carcinoma pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Merkel Cell Carcinoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Merkel Cell Carcinoma Treatment.
* Merkel Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Merkel Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Merkel Cell Carcinoma market.
Explore the dynamic world of drug development with our latest Merkel Cell Carcinoma Pipeline Insights report! Don't miss this opportunity to stay informed-download now! @ Merkel Cell Carcinoma Treatment Drugs [https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Merkel Cell Carcinoma Companies
ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.
Merkel Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
* Molecule Type
Merkel Cell Carcinoma Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Stay updated with the latest Merkel Cell Carcinoma Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Merkel Cell Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Merkel Cell Carcinoma Pipeline Report
* Coverage- Global
* Merkel Cell Carcinoma Companies- ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, Sensei Biotherapeutics and others.
* Merkel Cell Carcinoma Therapies- Avelumab, Pembrolizumab, MLN0128, KRT-232, Retifanlimab, Ipilimumab and others.
* Merkel Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Merkel Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which Merkel Cell Carcinoma Companies are leading the way in drug discovery? Download now to stay at the forefront of pharmaceutical innovation!" @ Merkel Cell Carcinoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Merkel Cell Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Mid Stage Products (Phase II)
* Domatinostat: 4SC
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* XmAb18087: Xencor
* Drug profiles in the detailed report.....
* Preclinical stage products
* SNS-401-NG: Sensei Biotherapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Merkel Cell Carcinoma Key Companies
* Merkel Cell Carcinoma Key Products
* Merkel Cell Carcinoma- Unmet Needs
* Merkel Cell Carcinoma- Market Drivers and Barriers
* Merkel Cell Carcinoma- Future Perspectives and Conclusion
* Merkel Cell Carcinoma Analyst Views
* Merkel Cell Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=merkel-cell-carcinoma-pipeline-outlook-report-2025-key-14-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/merkel-cell-carcinoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Merkel Cell Carcinoma Pipeline Outlook Report 2025: Key 14+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4146468 • Views: …
More Releases from ABNewswire
HER2-Negative Breast Cancer Pipeline Outlook Report 2025: Key 70+ Companies and …
DelveInsight's, "HER2-Negative Breast Cancer Pipeline Insight" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-Negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the…
Metastatic Melanoma Pipeline Outlook Report 2025: Key 75+ Companies and Breakthr …
DelveInsight's, "Metastatic Melanoma Pipeline Insight, 2025" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Metastatic Melanoma pipeline landscape. It covers the Metastatic Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the…
Ulcerative Colitis Pipeline Outlook Report 2025: Key 70+ Companies and Breakthro …
DelveInsight's, "Ulcerative Colitis Pipeline Insight 2025" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ulcerative Colitis Pipeline Landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ulcerative Colitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and…
T-Cell Prolymphocytic Leukemia Pipeline Outlook Report 2025: Key 5+ Companies an …
DelveInsight's, "T-cell-Prolymphocytic-Leukemia Pipeline Insight 2025" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in T-cell-Prolymphocytic-Leukemia pipeline landscape. It covers the T-Cell Prolymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the T-Cell Prolymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…
More Releases for Merkel
Rising Incidence Of Skin Cancer Fuels Growth In Merkel Cell Carcinoma Treatment …
Which drivers are expected to have the greatest impact on the over the merkel cell carcinoma treatment market's growth?
The escalating occurrence rate of skin cancer cases is likely to stimulate the merkel cell carcinoma treatment market's expansion. Skin cancer refers to a specific variety of cancer that originates in the skin cells. It transpires when skin's normal cells experience genetic mutations that make them proliferate uncontrollably, leading to the creation…
Merkel Cell Carcinoma Treatment Market 2024 Research Report
Merkel Cell Carcinoma Treatment Market
Merkel cell carcinoma treatment includes medical interventions and therapies used to manage Merkel cell carcinoma, a rare and aggressive skin cancer.
The global Merkel Cell Carcinoma Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The market for Merkel cell carcinoma treatment is driven by the increasing incidence of…
Metastatic Merkel Cell Carcinoma Pipeline Outlook Report 2024 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Metastatic Merkel Cell Carcinoma pipeline constitutes 13+ key companies continuously working towards developing 15+ Metastatic Merkel Cell Carcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Metastatic Merkel Cell Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Metastatic Merkel…
Advanced Merkel Cell Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Advanced Merkel cell carcinoma Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Advanced Merkel cell carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Advanced Merkel Cell…
Global Merkel Cell Carcinoma Treatment Market Insights, Forecast
Merkel Cell Carcinoma, a skin malignancy, is caused by the uncontrolled development of Merkel cells in the skin. MCC was originally first described by Toker in 1972. The malady is to a great extent caused by Merkel Cell Polyomavirus (MCV) on parts of the skin in the head, neck and arms, generally occurs most often on sun-exposed areas of the skin. The global Merkel Cell Carcinoma Treatment market is…
Merkel Cell Carcinoma - Pipeline Review, H1 2017
Market Research Hub includes new market research report "Merkel Cell Carcinoma - Pipeline Review, H1 2017" to its huge collection of research reports.
Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts…
